Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sensei Biotherapeutics ( (SNSE) ) has issued an announcement.
On December 22, 2025, Sensei Biotherapeutics, Inc. entered into amended retention agreements with President and Principal Executive Officer Christopher Gerry and Senior Vice President of Finance and Principal Finance and Accounting Officer Josiah Craver, revising key compensatory terms in their employment arrangements. Effective November 14, 2025, the company set Gerry’s annual base salary at $425,000 and Craver’s at $400,000 and made both executives eligible for an annual target bonus equal to 40% of base salary beginning with the 2026 fiscal year; it also established a structure of retention bonuses tied to continued employment into early 2026 or to certain termination scenarios, with enhanced benefits if they are terminated without cause or resign for good reason outside the context of a change in control, contingent on signing a separation and release agreement. The changes strengthen management’s financial incentives to remain with the company during a critical period, potentially providing greater leadership stability and signaling a focus on executive retention to investors and other stakeholders.
The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Underperform.
Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. is a biotechnology company, although this disclosure does not provide details on its specific therapeutic focus, products, or market strategy, and instead centers on changes to executive compensation and retention arrangements for its senior leadership team.
Average Trading Volume: 69,176
Technical Sentiment Signal: Buy
Current Market Cap: $11.18M
For detailed information about SNSE stock, go to TipRanks’ Stock Analysis page.